| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2021: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2020: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2019: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2018: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
|
|---|
| Outline of Final Research Achievements |
Drug-resistant cell lines were generated using various bone and soft-tissue tumor cell lines. Among them, we successfully established multiple drug-resistant bone and soft tissue tumor cell lines by repeated administration of drugs to cell lines such as a liposarcoma cell line and a malignant peripheral nerve sheath tumor cell line. Using the established drug-resistant bone and soft tissue tumor-derived cell lines, we performed comprehensive gene and protein expression analysis of genes and proteins involved in drug resistance in the cell lines before and after the acquisition of drug resistance, respectively. We also conducted exploratory studies on the mechanisms of drug action and novel therapeutic targets for giant cell tumor of bone, for which denosumab is being applied to clinical practice as a novel therapeutic agent and for chondrosarcoma, for which no effective drug therapy exists.
|
